23:36 , Jul 15, 2019 |  BC Extra  |  Company News

Via Mavupharma takeout, AbbVie gets first-in-class STING target

The acquisition of Mavupharma gives AbbVie a first-in-class indirect STING booster close to the clinic that inhibits a target unexploited by other companies in oncology. James Topper of Frazier Healthcare Partners, which led three-year-old Mavupharma...
00:10 , Jun 4, 2019 |  BC Innovations  |  Distillery Techniques

Tool compounds for probing the role of human cGAS in inflammatory diseases

TECHNIQUES CATEGORY: Chemistry TECHNOLOGY: Tool compound Small molecule inhibitors of human cGAS could be used to probe the role of cGAS-dependent signaling in inflammatory diseases. Screening of a compound library followed by optimization of the...
00:07 , Mar 7, 2019 |  BC Extra  |  Preclinical News

STING structures reveal target sites

A trio of papers co-led by Zhijian “James” Chen revealed the molecular structure of STING in complex with two factors in its signaling pathway and a new function -- autophagy induction. The findings, reported in...
01:17 , Feb 16, 2019 |  BC Extra  |  Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

In a week that had a pair of innovative Chinese companies raise early venture rounds and a Bay Area company debut its digital biomanufacturing platform, the biggest series A round went to Philadelphia gene therapy...
23:28 , Feb 13, 2019 |  BC Week In Review  |  Company News

IFM launches subsidiary for cGAS, STING inhibitors

IFM Therapeutics LLC (Boston, Mass.) launched IFM Due Inc., a subsidiary that intends to develop inhibitors of cGAS and STING to treat autoimmune and inflammatory diseases. The subsidiary also named immunologist Andrea Ablasser, a professor...
20:26 , Feb 11, 2019 |  BC Extra  |  Company News

IFM launches subsidiary for cGAS, STING inhibitors

IFM Therapeutics LLC (Boston, Mass.) launched IFM Due Inc., a subsidiary that intends to develop inhibitors of cGAS and STING to treat autoimmune and inflammatory diseases. The subsidiary also named immunologist Andrea Ablasser, a professor...
13:52 , Jan 29, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest polymer vesicles loaded with the STING agonist cGAMP could help treat melanoma. The vesicles consist of cGAMP encapsulated in a polyethylene glycol (PEG)-based polymer membrane based on pH-sensitive, cationic diethylamino-based...
19:28 , Dec 21, 2018 |  BC Week In Review  |  Company News

Lilly licenses Aduro's STING inhibitors

Eli Lilly and Co. (NYSE:LLY) received an exclusive license from Aduro Biotech Inc. (NASDAQ:ADRO) for its cGAS-STING inhibitor platform to develop immunotherapies for autoimmune and inflammatory diseases. Aduro will receive $12 million up front and...
02:11 , Dec 19, 2018 |  BC Extra  |  Company News

Lilly licenses Aduro’s STING inhibitors

Eli Lilly and Co. (NYSE:LLY) received an exclusive license from Aduro Biotech Inc. (NASDAQ:ADRO) for its cGAS-STING inhibitor platform to develop immunotherapies for autoimmune and inflammatory diseases. Aduro will receive $12 million up front and...
22:10 , Nov 7, 2018 |  BC Extra  |  Preclinical News

GSK’s systemic STING agonist could overcome delivery hurdles

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) researchers have developed a STING agonist that can be delivered systemically as opposed to intratumorally, which can overcome challenges of accessing hard to reach tumors or cancers that have spread. At...